ASPR awards $110 million to advance development, procure therapeutic for Sudan ebolavirus
The Administration for Strategic Preparedness and Response (ASPR) today announced a $109.8 million contract with Mapp Biopharmaceutical Inc., for the advanced development and potential purchase of a monoclonal antibody therapeutic to treat Sudan ebolavirus (SUDV).